## Surgical Management of Bethesda Category IV Nodules ### Classification and Risk Stratification **Key Point:** Bethesda Category IV (atypia of undetermined significance, AUS) carries a malignancy risk of 10–40%, intermediate between benign (Bethesda I–II, <5%) and suspicious for malignancy (Bethesda V, 50–75%). ### ATA Guidelines for Bethesda IV Nodules The American Thyroid Association (ATA) 2015 guidelines recommend: 1. **Repeat FNAC** — if the repeat is benign, follow-up ultrasound is appropriate 2. **Molecular testing** (ThyroSeq, Afirma) — if available and positive for mutations, proceed to surgery 3. **Surgical approach if proceeding** — **lobectomy is the initial procedure of choice** for nodules confined to one lobe without evidence of extrathyroidal extension or suspicious lymph nodes ### Why Lobectomy (Option 0) is Correct | Feature | Lobectomy | Total Thyroidectomy | |---------|-----------|--------------------| | **Indication** | Bethesda IV, confined nodule, no ETE, no suspicious nodes | Confirmed malignancy, bilateral disease, or high-risk features | | **Thyroid hormone replacement** | Often unnecessary | Always required | | **Hypoparathyroidism risk** | Lower | Higher (bilateral dissection) | | **Recurrent laryngeal nerve injury** | Lower (unilateral) | Higher (bilateral dissection) | | **Radioactive iodine ablation** | Not indicated for benign/AUS | Indicated for differentiated thyroid cancer | **Clinical Pearl:** Lobectomy is diagnostic and therapeutic. If final histopathology shows malignancy (papillary, follicular carcinoma), completion thyroidectomy can be performed at a second stage based on tumor size, grade, and stage. This staged approach avoids unnecessary total thyroidectomy in cases that prove benign on final pathology. **High-Yield:** The key principle is **conservative initial surgery for indeterminate nodules**. Overtreatment (total thyroidectomy for AUS) exposes patients to unnecessary morbidity (permanent hypothyroidism, hypoparathyroidism) when 60–90% of AUS nodules are benign. ### Why Other Options Are Incorrect **Option 1 (Total thyroidectomy with prophylactic central neck dissection):** - Reserved for confirmed thyroid cancer with high-risk features or bilateral disease - Prophylactic central neck dissection is NOT recommended for indeterminate nodules without evidence of nodal metastases - Increases morbidity without proven benefit in the AUS setting **Option 2 (Total thyroidectomy followed by RAI ablation):** - RAI ablation is indicated ONLY for differentiated thyroid cancer (DTC) with risk factors for recurrence - Bethesda IV is indeterminate; 60–90% are benign - Ablating benign thyroid tissue is inappropriate and exposes the patient to unnecessary radiation **Option 3 (Subtotal thyroidectomy preserving 5–10 g):** - Subtotal thyroidectomy is an outdated approach, largely abandoned in modern practice - Associated with higher recurrence rates and persistent hyperthyroidism if the patient has Graves' disease (not the case here) - Current guidelines favor either lobectomy (for indeterminate/benign) or total thyroidectomy (for cancer) ```mermaid flowchart TD A[Thyroid nodule + FNAC]:::outcome --> B{Bethesda category?}:::decision B -->|I-II Benign| C[Follow-up ultrasound]:::action B -->|III AUS| D{Molecular testing available?}:::decision B -->|IV AUS| E[Consider molecular testing]:::action B -->|V Suspicious| F[Lobectomy]:::action B -->|VI Malignant| G[Total thyroidectomy + staging]:::action E --> H{Mutation/high-risk molecular?}:::decision H -->|Yes| I[Lobectomy]:::action H -->|No| J[Repeat FNAC or follow-up]:::action D -->|Positive| I D -->|Negative| J I --> K{Final pathology shows cancer?}:::decision K -->|Yes| L[Completion thyroidectomy + RAI if indicated]:::action K -->|No| M[Observation]:::outcome ``` [cite:ATA Thyroid Nodule Guidelines 2015]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.